SCM
Silverarc Capital Management’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.04M | Sell |
198,441
-7,521
| -4% | -$153K | 0.74% | 28 |
|
|
2025
Q1 | $3.74M | Sell |
205,962
-58,598
| -22% | -$1.06M | 0.76% | 33 |
|
|
2024
Q4 | $6.69M | Buy |
264,560
+119,560
| +82% | +$3.02M | 1.46% | 24 |
|
|
2024
Q3 | $4.93M | Sell |
145,000
-229,910
| -61% | -$7.81M | 1.11% | 34 |
|
|
2024
Q2 | $13.9M | Buy |
374,910
+75,594
| +25% | +$2.8M | 3.27% | 8 |
|
|
2024
Q1 | $12.6M | Buy |
299,316
+52,101
| +21% | +$2.19M | 3.49% | 6 |
|
|
2023
Q4 | $9.8M | Buy |
+247,215
| New | +$9.8M | 2.92% | 11 |
|
|
2023
Q3 | – | Sell |
-10,000
| Closed | -$339K | – | 73 |
|
|
2023
Q2 | $339K | Sell |
10,000
-74,651
| -88% | -$2.53M | 0.11% | 68 |
|
|
2023
Q1 | $3.05M | Buy |
84,651
+29,952
| +55% | +$1.08M | 1.26% | 27 |
|
|
2022
Q4 | $2.44M | Buy |
54,699
+1,424
| +3% | +$63.5K | 0.7% | 43 |
|
|
2022
Q3 | $1.5M | Buy |
53,275
+16,953
| +47% | +$477K | 0.51% | 45 |
|
|
2022
Q2 | $979K | Sell |
36,322
-9,216
| -20% | -$248K | 0.3% | 45 |
|
|
2022
Q1 | $256 | Buy |
45,538
+406
| +0.9% | +$2 | 0.11% | 57 |
|
|
2021
Q4 | $1.74M | Buy |
45,132
+6,889
| +18% | +$266K | 0.71% | 40 |
|
|
2021
Q3 | $2.07M | Buy |
38,243
+28,322
| +285% | +$1.53M | 1.17% | 26 |
|
|
2021
Q2 | $2.93K | Buy |
+9,921
| New | +$2.93K | 1.31% | 24 |
|
|
2021
Q1 | – | Sell |
-80,282
| Closed | -$1.41M | – | 91 |
|
|
2020
Q4 | $1.41M | Buy |
+80,282
| New | +$1.41M | 0.82% | 42 |
|